ATE121296T1 - Igf-i zur behandlung von nebeneffekten der steroidtherapie. - Google Patents

Igf-i zur behandlung von nebeneffekten der steroidtherapie.

Info

Publication number
ATE121296T1
ATE121296T1 AT90810987T AT90810987T ATE121296T1 AT E121296 T1 ATE121296 T1 AT E121296T1 AT 90810987 T AT90810987 T AT 90810987T AT 90810987 T AT90810987 T AT 90810987T AT E121296 T1 ATE121296 T1 AT E121296T1
Authority
AT
Austria
Prior art keywords
igf
treatment
side effects
steroid therapy
steroid
Prior art date
Application number
AT90810987T
Other languages
English (en)
Inventor
Ronald L Goldberg
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE121296T1 publication Critical patent/ATE121296T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/30Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT90810987T 1989-12-22 1990-12-13 Igf-i zur behandlung von nebeneffekten der steroidtherapie. ATE121296T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45521589A 1989-12-22 1989-12-22

Publications (1)

Publication Number Publication Date
ATE121296T1 true ATE121296T1 (de) 1995-05-15

Family

ID=23807878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90810987T ATE121296T1 (de) 1989-12-22 1990-12-13 Igf-i zur behandlung von nebeneffekten der steroidtherapie.

Country Status (14)

Country Link
EP (1) EP0434625B1 (de)
JP (1) JP2934023B2 (de)
KR (1) KR100191381B1 (de)
AT (1) ATE121296T1 (de)
AU (1) AU641966B2 (de)
CA (1) CA2032859C (de)
DE (1) DE69018799T2 (de)
DK (1) DK0434625T3 (de)
ES (1) ES2071080T3 (de)
GR (1) GR3015900T3 (de)
IE (1) IE67510B1 (de)
IL (1) IL96711A (de)
NZ (1) NZ236614A (de)
ZA (1) ZA9010332B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
WO1996007744A1 (en) * 1994-09-08 1996-03-14 Chiron Corporation A method of improved production of insulin-like growth factor
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU7271996A (en) * 1995-10-23 1997-05-15 Queen's University At Kingston Method and pharmaceutical composition for chondrostimulation with a prostaglandin (e.g. misoprostol) and tgf-beta, optionally in combination with igf-1
EP0956041A1 (de) * 1996-09-16 1999-11-17 Dalhousie University Verwendung von igf-1 zur behandlung von polyzystischer nierenkrankheit und damit verbundene indikationen
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
AU3548999A (en) 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子(igf)i突然変異体
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
CA2617578C (en) 2005-08-01 2013-12-17 Genera Doo Methods and compositions for regenerating articular cartilage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003409A1 (en) * 1986-11-14 1988-05-19 Institute Of Molecular Biology, Inc. Wound healing and bone regeneration
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β

Also Published As

Publication number Publication date
AU6824790A (en) 1991-06-27
CA2032859C (en) 2007-09-17
EP0434625A2 (de) 1991-06-26
IL96711A0 (en) 1991-09-16
ES2071080T3 (es) 1995-06-16
JPH04210648A (ja) 1992-07-31
DE69018799T2 (de) 1995-09-21
IE67510B1 (en) 1996-04-03
ZA9010332B (en) 1991-08-28
DE69018799D1 (de) 1995-05-24
IL96711A (en) 1996-01-19
EP0434625A3 (en) 1991-10-02
AU641966B2 (en) 1993-10-07
KR910011279A (ko) 1991-08-07
KR100191381B1 (ko) 1999-06-15
GR3015900T3 (en) 1995-07-31
NZ236614A (en) 1993-10-26
IE904684A1 (en) 1991-07-17
CA2032859A1 (en) 1991-06-23
DK0434625T3 (da) 1995-06-26
JP2934023B2 (ja) 1999-08-16
EP0434625B1 (de) 1995-04-19

Similar Documents

Publication Publication Date Title
ATE121296T1 (de) Igf-i zur behandlung von nebeneffekten der steroidtherapie.
ATE118172T1 (de) Zusammensetzung und verfahren für die behandlung von osteoporose bei säugetieren.
ATE187889T1 (de) Vorbeugung und behandlung der peripheren neuropathie
ATE186840T1 (de) Zusammensetzungen und methoden zur wundbehandlung
DE69031939D1 (de) Osteoinduktive zusammensetzungen
ATE223486T1 (de) Bmp-9 zusammensetzungen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE3677400D1 (de) Verfahren zur behandlung von knochenersatz-implantaten.
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
DE3851584D1 (de) Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE178206T1 (de) Verfahren zur vorbeugung und behandlung von durch chemotherapie ausgelöster alopezie
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE59103291D1 (de) Verfahren zur bekämpfung von samen- und/oder bodenbürtigen schaderregern durch saatgutbehandlung.
ATE110961T1 (de) Behandlung von beatmungsabhängigkeit mit wachstumshormon.
ATE127118T1 (de) 2-alkyl-3-benzoylbenzofurane zur behandlung von herzarrhythmia.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee